The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[<sup>18</sup>F] fluoroethyl-)-L-t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/12/6787 |
| _version_ | 1797486348556304384 |
|---|---|
| author | Marija Skoblar Vidmar Andrej Doma Uroš Smrdel Katarina Zevnik Andrej Studen |
| author_facet | Marija Skoblar Vidmar Andrej Doma Uroš Smrdel Katarina Zevnik Andrej Studen |
| author_sort | Marija Skoblar Vidmar |
| collection | DOAJ |
| description | The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[<sup>18</sup>F] fluoroethyl-)-L-tyrosine (<sup>18</sup>F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different <sup>18</sup>F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of <sup>18</sup>F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic <sup>18</sup>F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup. |
| first_indexed | 2024-03-09T23:31:55Z |
| format | Article |
| id | doaj.art-2cf54a3ecc0d4a82a323abc1d60ffeaa |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T23:31:55Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2cf54a3ecc0d4a82a323abc1d60ffeaa2023-11-23T17:06:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-06-012312678710.3390/ijms23126787The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular BiomarkersMarija Skoblar Vidmar0Andrej Doma1Uroš Smrdel2Katarina Zevnik3Andrej Studen4Division of Radiotherapy, Institute of Oncology Ljubljana, 1000 Ljubljana, SloveniaDepartment of Nuclear Medicine, Institute of Oncology Ljubljana, 1000 Ljubljana, SloveniaDivision of Radiotherapy, Institute of Oncology Ljubljana, 1000 Ljubljana, SloveniaDepartment of Nuclear Medicine, Institute of Oncology Ljubljana, 1000 Ljubljana, SloveniaExperimental Particle Physics Department, Jožef Stefan Institute, 1000 Ljubljana, SloveniaThe evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[<sup>18</sup>F] fluoroethyl-)-L-tyrosine (<sup>18</sup>F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different <sup>18</sup>F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of <sup>18</sup>F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic <sup>18</sup>F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup.https://www.mdpi.com/1422-0067/23/12/6787gliomatreatment-related changestrue progressionpseudoprogressionradiation necrosisbiomarkers |
| spellingShingle | Marija Skoblar Vidmar Andrej Doma Uroš Smrdel Katarina Zevnik Andrej Studen The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers International Journal of Molecular Sciences glioma treatment-related changes true progression pseudoprogression radiation necrosis biomarkers |
| title | The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers |
| title_full | The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers |
| title_fullStr | The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers |
| title_full_unstemmed | The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers |
| title_short | The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers |
| title_sort | value of fet pet ct in recurrent glioma with a different idh mutation status the relationship between imaging and molecular biomarkers |
| topic | glioma treatment-related changes true progression pseudoprogression radiation necrosis biomarkers |
| url | https://www.mdpi.com/1422-0067/23/12/6787 |
| work_keys_str_mv | AT marijaskoblarvidmar thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT andrejdoma thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT urossmrdel thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT katarinazevnik thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT andrejstuden thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT marijaskoblarvidmar valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT andrejdoma valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT urossmrdel valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT katarinazevnik valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers AT andrejstuden valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers |